Juvenile hemochromatosis gene (HFE2A) cleavage products and uses thereof
AssigneeXenon Pharmaceuticals Inc.
InventorsYigal P. Goldberg, Rajender K. Kamboj
Life of this patent
Estimating the term…
Loading patent…
AssigneeXenon Pharmaceuticals Inc.
InventorsYigal P. Goldberg, Rajender K. Kamboj
Estimating the term…
Isolated fragments of the HFE2A protein able to bind and modulate HFE2A and other proteins, such as hepcidin, involved in the iron metabolism pathway are disclosed, such fragments being of molecular weight of approximately 7 kDa to 43 kDa. Also disclosed are corresponding isolated polynucleotides encoding the fragments of the HFE2A protein. The invention includes derivatives and analogs of the polypeptide fragments of HFE2A, along with compositions of these, that are functionally active, i.e. capable of interacting with the HFE2A, as well as methods of production of the HFE2A cleavage products, derivatives and analogs, e.g. by recombinant means. Methods for identifying modulators of HFE2A, comprising contacting a test compound with HFE2A and determining a change in HFE2A activity due to the compound, are provided. Also taught are methods of diagnosing an animal afflicted with or at risk of developing a disease of iron metabolism comprising determining a change in the level, amount or activity of a fragment of an HFE2A obtained in a sample from said animal relative to the level, amount or activity of a fragment of an HFE2A obtained in a control sample from an unaffected animal, wherein a change identifies said individual as being affect by or at risk of developing a disease of iron metabolism. Methods for treating and/or preventing a disorder in animals comprising administering to an animal afflicted therewith, or at risk of developing said disorder, a therapeutically effective amount of an HFE2A modulator are provided.
1-13. (canceled)
A recombinant cell engineered to express a polypeptide comprising an amino acid sequence with at least 80% identity to an amino acid sequence selected from the group consisting of SEQ ID NO:
15-17. (canceled)
An isolated polynucleotide encoding a polypeptide having an amino acid sequence with at least 80% identity to an amino acid sequence selected from the group consisting of SEQ ID NO:
19-21. (canceled)
A method to diagnose individuals afflicted with or at risk of developing a disease of iron metabolism comprising:
26-27. (canceled)
(canceled)
(canceled)
34-35. (canceled)
37-43. (canceled)
A method for identifying an agent that modulates the activity or level of an HFE2A polypeptide, comprising:
45-46. (canceled)
48-50. (canceled)
53-55. (canceled)
A method for identifying an agent that modulates the activity of HFE2A polynucleotide, comprising:
57-58. (canceled)
A method for treating a disease of iron metabolism comprising administering to an individual afflicted therewith a therapeutically effective amount of a modulator of an HFE2A, wherein said modulator is selected from the group consisting of agonists to HFE2A, antagonists to the HFE2A, agonists to a fragment of the HFE2A polypeptide, antagonists to a fragment of the HFE2A polypeptide, including pharmaceutically acceptable salts thereof and combinations of these.
61-70. (canceled)
Dependencies are inferred from the claim text.